Targeting drug-delivery nanoparticles to sites of inflammation

将药物输送纳米颗粒靶向炎症部位

• 批准号: 7109581
• 负责人: HENRY Jerrold KAPLAN
• 金额: $ 34.27万
• 依托单位: POTENTIA PHARMACEUTICALS, INC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7109581
• 关键词: aging; angiogenesis; birth; blindness; blood vessels; drug delivery systems; emotions; eye; inflammation; lasers; lead; macular degeneration; model; particle; person with disability; selectins; vision

DESCRIPTION (provided by applicant): The purpose of this project is to develop a nanoparticle-based drug delivery system for use in the treatment of the exudative form of aged-related macular degeneration (ARMD). ARMD is the leading cause of blindness for individuals over fifty-five years of age that live in the industrialized world. It affects approximately 10 million people in the US and as many as 30 million worldwide. There are two forms of the disease, both of which cause a loss of central vision. Approximately eighty-five percent of patients have the less severe dry form that produces gradual but rarely complete vision loss. The remaining fifteen percent have the severe wet, or exudative, form that causes rapid, disabling blindness. Wet ARMD is further characterized by choroidal neovascularization (CNV), a growth under the macula of abnormal blood vessels originating from the choroidal capillary bed. Research has linked chronic inflammation to both forms of ARMD. The advent of novel anti-angiogenic agents has enabled pharmaceutical treatment of ARMD but only for the wet form of the disease. These treatments are severely limited by the fact that the drug must be directly injected into the eye. This procedure carries a significant risk of complication and generates understandable issues of patient acceptability. Estimates predict that as many as one half of patients will discontinue treatment because of ocular injection. Thus, there is a clear need for a therapy that either bypasses the need for ocular injection or reduces its frequency. The chitosan-based nanoparticle delivery system we propose to develop intends to meet this need. Successful completion of this Phase I project will result in a prototype nanoparticle that can be injected intravenously and home to inflamed blood vessels in the eye and release an anti-angiogenic agent locally over a period of weeks to months.

描述（由申请人提供）：该项目的目的是开发一种基于纳米颗粒的药物输送系统，用于治疗与老年相关的黄斑变性（ARMD）的渗出形式。 ARMD是五十五岁以上生活在工业化世界中的个人失明的主要原因。它影响了美国约1000万人，全球多达3000万。该疾病有两种形式，两者都会导致中央视力丧失。大约85％的患者的干燥形式不太严重，会产生逐渐但很少完全的视力丧失。其余15％的人具有严重的湿润或渗出性形式，会导致快速，致命的失明。湿臂的进一步特征是脉络膜新生血管形成（CNV），这是一种来自脉络膜毛细血管床的异常血管下的生长。研究将慢性炎症与两种形式的ARMD联系起来。新型抗血管生成剂的出现使ARMD的药物治疗能够治疗，但仅针对该疾病的湿形式。这些治疗方法受到直接注射到眼睛的事实受到严重限制。该过程具有并发症的重大风险，并产生了可理解的患者可接受性问题。估计预测，多达一半的患者会因眼部注射而停止治疗。因此，很明显需要进行治疗，该治疗绕过需要眼注射或降低其频率的需求。我们提出的基于壳聚糖的纳米颗粒输送系统旨在满足这种需求。该阶段I项目的成功完成将导致一个原型纳米颗粒，可以静脉注射，并在眼睛中发炎的血管发炎，并在数周到几个月内释放局部抗血管生成剂。